The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study

Children and adolescents are more likely than adults to experience adverse side effects when taking antipsychotics. Pharmacogenetic testing allows one to more accurately choose the initial dose of a drug. The genes of pharmacokinetic factors have been shown to be of high prognostic value for the saf...

Full description

Bibliographic Details
Main Authors: D. V. Ivashchenko, S. Z. Khoang, M. Kh. Tazagulova, B. V. Makhmudova, N. I. Buromskaya, P. V. Shimanov, R. V. Deitch, I. V. Dorina, M. I. Nastovich, K. A. Akmalova, A. A. Kachanova, E. A. Grishina, L. M. Savchenko, Yu. S. Shevchenko, D. A. Sychev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2020-10-01
Series:Nevrologiâ, Nejropsihiatriâ, Psihosomatika
Subjects:
Online Access:https://nnp.ima-press.net/nnp/article/view/1324
id doaj-7997357ca57c4d20be84eae91f17b21f
record_format Article
spelling doaj-7997357ca57c4d20be84eae91f17b21f2021-07-29T08:58:41ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422020-10-01125243110.14412/2074-2711-2020-5-24-31985The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot studyD. V. Ivashchenko0S. Z. Khoang1M. Kh. Tazagulova2B. V. Makhmudova3N. I. Buromskaya4P. V. Shimanov5R. V. Deitch6I. V. Dorina7M. I. Nastovich8K. A. Akmalova9A. A. Kachanova10E. A. Grishina11L. M. Savchenko12Yu. S. Shevchenko13D. A. Sychev14Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaM.V. Lomonosov Moscow State UniversityG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaChildren and adolescents are more likely than adults to experience adverse side effects when taking antipsychotics. Pharmacogenetic testing allows one to more accurately choose the initial dose of a drug. The genes of pharmacokinetic factors have been shown to be of high prognostic value for the safety of antipsychotics in adults.Patients and methods. The study enrolled 36 adolescents (58.3% male) (mean age, 14.83±1.84 years). All the patients took an antipsychotic. The follow-up lasted 28 days. On 14 and 28 days of treatment, its efficiency and safety were evaluated using the Children's Global Assessment Scale (CGAS), the Positive and Negative Syndrome Scale (PANSS), the Udvalg for Kliniske Undersњgelser Side Effects Rating Scale (UKU-SERS), the Simpson-Angus Scale (SAS), and the Barnes Akathisia Rating Scale (BARS). The patients were genotyped for CYP3A4*22, CYP3A5*3, CYP2D6*4, *9, *10, ABCB1 1236C>T, 2677G>T/A, 3435C>T, DRD2 rs1800497, DRD4 rs1800955, and HTR2A rs6313.Results and discussion. The decrease in the mean score of the PANSS subscale “Productive symptoms” was more pronounced in carriers of the DRD2 rs1800497 polymorphic variant (-6.5 [-10.25; -3.75] vs -3 [-6.5; -2 ] on 14 day (p=0.028) and (-11 [-13; -9.5] vs -5 [-9; -3.5] on 28 day (p=0.001) compared to baseline. The carriage of ABCB1 3435CT+TT was associated with worse tolerance to pharmacotherapy on 14 day (the total score of the UKU-SERS M, 8 [3; 11.75] vs M, 2 [1; 6]; p=0.034). The carriers of DRD2 rs1800497 reported a greater severity of antipsychotic-induced neurological disorders (UKU-SERS subscale score M, 1 [0; 2.25] vs M 0 [0; 1]; p=0.029).Conclusion. The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T were established to be significantly associated with the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode.https://nnp.ima-press.net/nnp/article/view/1324pharmacogeneticsantipsychoticsadolescentsacute psychotic episodesafetyefficacy
collection DOAJ
language Russian
format Article
sources DOAJ
author D. V. Ivashchenko
S. Z. Khoang
M. Kh. Tazagulova
B. V. Makhmudova
N. I. Buromskaya
P. V. Shimanov
R. V. Deitch
I. V. Dorina
M. I. Nastovich
K. A. Akmalova
A. A. Kachanova
E. A. Grishina
L. M. Savchenko
Yu. S. Shevchenko
D. A. Sychev
spellingShingle D. V. Ivashchenko
S. Z. Khoang
M. Kh. Tazagulova
B. V. Makhmudova
N. I. Buromskaya
P. V. Shimanov
R. V. Deitch
I. V. Dorina
M. I. Nastovich
K. A. Akmalova
A. A. Kachanova
E. A. Grishina
L. M. Savchenko
Yu. S. Shevchenko
D. A. Sychev
The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
Nevrologiâ, Nejropsihiatriâ, Psihosomatika
pharmacogenetics
antipsychotics
adolescents
acute psychotic episode
safety
efficacy
author_facet D. V. Ivashchenko
S. Z. Khoang
M. Kh. Tazagulova
B. V. Makhmudova
N. I. Buromskaya
P. V. Shimanov
R. V. Deitch
I. V. Dorina
M. I. Nastovich
K. A. Akmalova
A. A. Kachanova
E. A. Grishina
L. M. Savchenko
Yu. S. Shevchenko
D. A. Sychev
author_sort D. V. Ivashchenko
title The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
title_short The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
title_full The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
title_fullStr The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
title_full_unstemmed The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
title_sort polymorphic variants drd2 rs1800497 and abcb1 3435c>t are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
publisher IMA-PRESS LLC
series Nevrologiâ, Nejropsihiatriâ, Psihosomatika
issn 2074-2711
2310-1342
publishDate 2020-10-01
description Children and adolescents are more likely than adults to experience adverse side effects when taking antipsychotics. Pharmacogenetic testing allows one to more accurately choose the initial dose of a drug. The genes of pharmacokinetic factors have been shown to be of high prognostic value for the safety of antipsychotics in adults.Patients and methods. The study enrolled 36 adolescents (58.3% male) (mean age, 14.83±1.84 years). All the patients took an antipsychotic. The follow-up lasted 28 days. On 14 and 28 days of treatment, its efficiency and safety were evaluated using the Children's Global Assessment Scale (CGAS), the Positive and Negative Syndrome Scale (PANSS), the Udvalg for Kliniske Undersњgelser Side Effects Rating Scale (UKU-SERS), the Simpson-Angus Scale (SAS), and the Barnes Akathisia Rating Scale (BARS). The patients were genotyped for CYP3A4*22, CYP3A5*3, CYP2D6*4, *9, *10, ABCB1 1236C>T, 2677G>T/A, 3435C>T, DRD2 rs1800497, DRD4 rs1800955, and HTR2A rs6313.Results and discussion. The decrease in the mean score of the PANSS subscale “Productive symptoms” was more pronounced in carriers of the DRD2 rs1800497 polymorphic variant (-6.5 [-10.25; -3.75] vs -3 [-6.5; -2 ] on 14 day (p=0.028) and (-11 [-13; -9.5] vs -5 [-9; -3.5] on 28 day (p=0.001) compared to baseline. The carriage of ABCB1 3435CT+TT was associated with worse tolerance to pharmacotherapy on 14 day (the total score of the UKU-SERS M, 8 [3; 11.75] vs M, 2 [1; 6]; p=0.034). The carriers of DRD2 rs1800497 reported a greater severity of antipsychotic-induced neurological disorders (UKU-SERS subscale score M, 1 [0; 2.25] vs M 0 [0; 1]; p=0.029).Conclusion. The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T were established to be significantly associated with the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode.
topic pharmacogenetics
antipsychotics
adolescents
acute psychotic episode
safety
efficacy
url https://nnp.ima-press.net/nnp/article/view/1324
work_keys_str_mv AT dvivashchenko thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT szkhoang thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT mkhtazagulova thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT bvmakhmudova thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT niburomskaya thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT pvshimanov thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT rvdeitch thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT ivdorina thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT minastovich thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT kaakmalova thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT aakachanova thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT eagrishina thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT lmsavchenko thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT yusshevchenko thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT dasychev thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT dvivashchenko polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT szkhoang polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT mkhtazagulova polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT bvmakhmudova polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT niburomskaya polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT pvshimanov polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT rvdeitch polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT ivdorina polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT minastovich polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT kaakmalova polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT aakachanova polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT eagrishina polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT lmsavchenko polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT yusshevchenko polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
AT dasychev polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy
_version_ 1721250512298311680